CDK6 and familial pancreatic carcinoma: Altogether, our research provided further proof for the action of CDK6 in cancer progression, suggesting that nc‐RNA‐mediated high expression of CDK6 is associated with patient outcomes and immune invasion in pancreatic cancer.